Clinical Trials Logo

Recurrent Diffuse Intrinsic Pontine Glioma clinical trials

View clinical trials related to Recurrent Diffuse Intrinsic Pontine Glioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02359565 Recruiting - Malignant Glioma Clinical Trials

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors

Start date: May 22, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), or brain tumors with a high number of genetic mutations that have come back, progressed, or have not responded to previous treatment. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.